MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Frost & Sullivan
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Jamjoom Pharmaceuticals Earns Acclaim from Frost & Sullivan for its Dominance in the KSA Pharma Market - Jamjoom Pharmaceuticals Earns Acclaim from Frost & Sullivan for its Dominance in the KSA Pharma Market with its Expanded Portfolio and Geographic Presence - JamjoomPharma.com / Frost.com
Jamjoom Pharmaceuticals Earns Acclaim from Frost & Sullivan for its Dominance in the KSA Pharma Market

 

NewswireToday - /newswire/ - Jeddah, Saudi Arabia, 2020/08/19 - Jamjoom Pharmaceuticals Earns Acclaim from Frost & Sullivan for its Dominance in the KSA Pharma Market with its Expanded Portfolio and Geographic Presence - JamjoomPharma.com / Frost.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Based on its recent analysis of the KSA emerging generic pharmaceuticals market, Frost & Sullivan recognizes Saudi Arabia-headquartered Jamjoom Pharmaceuticals with the 2020 KSA Company of the Year Award for its operational excellence and expanded product portfolio and footprint. The company leads the KSA market by adopting sustainable business models and clear growth strategies. Implementing best practices, such as the corporate governance and setting up their own R&D center, recruiting qualified staff, strictly adhering to regulatory systems, and ensuring scalability, the company has established itself as the pharma partner of choice in the KSA.

“Despite a particularly challenging 2019, Jamjoom Pharmaceuticals recorded 4% year-on-year growth and maintained its position as one of the top-ranked pharma companies in the KSA,” said Dr. Suhasini, Associate Director Transformational Health. “Right from the start, it focused on building a world-class manufacturing facility. Its building design, layout, selection, and installation of equipment; plant validation; and other technical processes met the most stringent international industry standards. Owing to its strategic diversification of specialty product lines and accelerating growth in export markets, Jamjoom Pharmaceuticals has been able to expand its manufacturing facilities and grow organically.”

Jamjoom Pharma is aiming to continue its journey of success, by continuously re-investing in cutting edge, state-of-the-art technologies, systems, people and facilities, to meet world-class quality standards and continue to produce products that meet and exceed the international standards. This is in line with its vision to become ‘A top-3 regional, research-driven branded generic pharmaceutical company. In addition, it works in line with the KSA Government’s Vision 2030 to achieve excellence in local manufacturing and provide the best in class, top of the range of of medicines. Jamjoom Pharma’s product portfolio is broadly classified into Dermatologicals, Ophthalmics, Gastrointestinal tract (GIT), Cardiovascular drugs (CVD), General Medicine (GM), and OTC product lines. Among these, the Ophthalmic and Dermatological lines have the highest market share and have historically been its most successful product lines.

Furthermore, to gain market share rapidly, Jamjoom Pharmaceuticals entered new markets with a successful, scientifically-supported methodology. It adopted a rationalized strategy to create customer demand by constantly developing high quality, superior formulations for normal wellbeing, whether Pharmaceuticals or Nutraceutical supplements, and combining it with intensive medical promotion. Besides raising the efficiency of the field force, the company also focused on expanding its product range, to cope with changing market dynamics.

One of the projects Jamjoom is particularly proud of is represented by the Jamjoom Pharma Academy, a state-of-the-art educational and training center with full access to Jamjoom Pharmaceutical’s R&D and quality control labs equipped with the latest manufacturing equipment and analytical techniques. This project is expected to be functional by the end of 2020.

“Jamjoom Pharmaceuticals has one of the largest qualified team of sales representatives in Saudi Arabia. This enables it to cover many doctors and hospitals,” noted Dr. Suhasini. “Overall, the company’s employee-friendly work culture, commitment to creating a strong brand image, participation and active involvement in KSA‘s Vision 2030, and emphasis on localization are expected to further accelerate its growth over the next two to three years.”

Each year, Frost & Sullivan presents a Company of the Year Award to the organization that demonstrates excellence in terms of growth strategy and implementation in its field. The award recognizes a high degree of innovation with products and technologies and the resulting leadership in terms of customer value and market penetration.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan

For over five decades, Frost & Sullivan (frost.com) has become world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, mega trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

About Jamjoom Pharmaceuticals

Jamjoom (jamjoompharma.com) is a GMP manufacturer and marketer of pharmaceutical products, over the counter medicines and health-related consumer products. It is considered one the fastest-growing company over the last decade; its core strategy is specialty line concept which enables Jamjoom Pharma to have a leading position in segments like Dermatology, Ophthalmology, GIT, and CVS.

Contact: H.Vilcu
P: +96 6126140099 - E: bdev[.]jamjoompharma.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Jamjoom Pharmaceuticals Earns Acclaim from Frost & Sullivan for its Dominance in the KSA Pharma Market

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Tarini Singh - Frost.com 
+91 20 67189725 tarini.singh[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ipsen to Present 12 Abstracts At the 11th World Congress for Neurorehabilitation (WCNR) Virtual Congress
Imec Announces elPrep5 - the Newest Version of its Software Platform for DNA Analysis
Ipsen Showcases Commitment to Patient-centric Advances in Oncology with Record Number of Abstracts to be Presented At ESMO 2020 Virtual Congress
Global Phase 3 Clinical Study of Pridopidine in Huntington’s Disease Announced
Ipsen to Present New Insights At ASBMR for Potential Treatment of Ultra-rare Disease Fibrodysplasia Ossificans Progressiva (FOP)
Ipsen to Present Results from MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP) At ASBMR 2020 Annual Meeting
DSM Ignites New Strategic Initiative to Transform Global Animal Nutrition and Health
DSM and Avril Complete Creation of Joint Venture to Develop Plant-based Protein
Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-small Cell Lung Cancer
Stevanato Group, SCHOTT, and Gerresheimer Confirm the Readiness to Support Future Covid-19 Vaccine with Pharmaceutical Containers
Ipsen Receives FDA Fast Track Designation for Liposomal Irinotecan (ONIVYDE®) as A First-line Combination Treatment for Metastatic Pancreatic Cancer
Ipsen Demonstrates Continued Commitment to Rare Diseases with Eight Abstracts Accepted At ENDO 2020 Published in the Journal of the Endocrine Society
Waters Corporation Earns New Product Innovation Award with First SmartMS-enabled Biopharmaceutical Solution
DSM Boosts Maternal and Infant Nutrition Portfolio with New Plant-based High Potency DHA Oil
Ipsen Enters into an Option Agreement with IRICoR and Université de Montréal for A Discovery-stage Oncology Program

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  JobsWare.com





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)